Project Grant R44CA306740
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85747, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $552,763 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on KAT6A as a novel therapeutic target for the treatment of high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). The research aims to characterize the epigenetic changes induced by KAT6 inhibitors,...
- The federal Project Grant award of $1,187,274.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant is supporting research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The research project aims to develop novel, plant-derived compounds that can serve as...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $918,976 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The award period runs from July 15, 2024 to July 14, 2027. The funding supports research activities to develop and evaluate novel, plant-derived compounds as...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $727,732 in funding to investigate combination therapy approaches to overcome resistance in dedifferentiated liposarcoma. The project aims to conduct a Phase Ib/II clinical trial evaluating the efficacy of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor mirdametinib. This builds upon previous research by...
- This Project Grant award of $549,474, provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395), aims to identify and validate specific inhibitors of the enzyme phosphoribosylformylglycinamidine synthase (PFAS) as a new class of purine antimetabolites for cancer treatment. The research seeks to address a fundamental gap in understanding how PFAS contributes to the progression of liver cancer, with the long-term goal of developing new...
- This federal Project Grant award for $657,776.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), will support the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The University of Pittsburgh, as the awardee, will engineer the anthrax toxin protein delivery system and the DUF5 toxin effector domain to create a potent and tumor-selective RAS inactivator. This innovative approach aims to address the...
- The National Cancer Institute awarded a $406,500 Project Grant to Trethera Corp under the Cancer Treatment Research program (CFDA 93.395) to fund the development of a novel, targeted small molecule inhibitor called TRE-515. The goal is to establish the deoxycytidine kinase (DCK) enzyme as a targetable resistance mechanism for KRAS inhibitors in non-small-cell lung cancer (NSCLC) models. The research will evaluate the improved efficacy of KRAS inhibitors when combined with TRE-515 in KRAS-G12C...